couter

002099.SZZhejiang Hisoar Pharmaceutical Co., Ltd.

This company has one year to prove it’s more than a mid-tier generic drugmaker — the next catalyst is the Q3 2026 earnings announcement on 2026-10-28, which will anchor the price at $5.60 and set the stage for either a bull move to $6.20 or a bear retreat to $5.30, with a lean toward the bull path at 54%. The next test is the National VBP Cycle Results on 2026-12-15, which could push the price to $6.64 or pull it back to $5.76, again with a slight edge to the bull. The company’s ability to deliver on these milestones will determine whether it’s seen as a value play or a growth story — and whether it can hold its own in a sector where margins are thin and competition is fierce.

Dec 15, 2026 — National VBP Cycle Results
Chart by TradingView

The schedule

  • Tue15Dec

    Release of results from the National Value-Based Payment (VBP) Cycle, which may impact reimbursement rates.

  • Wed20Jan

    Potential updates on US trade policy affecting pharmaceutical imports and exports.

  • Thu4Feb
  • Tue20Apr

    Full-year earnings announcement with updated guidance on performance and future outlook.

  • Thu6May
  • Thu5Aug

Past

  • Thu5Nov

    Quarterly earnings announcement with guidance on revenue and net income.

  • Tue15Sep

    Actual outcome: Bull · $6.15 at outcome

    The stock surged on strong earnings results and improved guidance, exceeding expectations in revenue and profit. The company reported better-than-anticipated performance, signaling stronger-than-expected demand and operational efficiency. This positive financial outlook likely drove the short-term price appreciation. [Market retrospective · Short-Term (6–10 days)] Missed anticipation: +18.6% from 2026-09-16 to 2026-10-08 (~2.1σ vs typical 10d vol). Target date 2026-09-25 reached; move through 2026-10-08 observed. Confidence 95%.

    The stock surged on strong earnings results and improved guidance, exceeding expectations in revenue and profit. The company reported better-than-anticipated performance, signaling stronger-than-expected demand and operational efficiency. This positive financial outlook likely drove the short-term price appreciation. [Market retrospective · Short-Term (6–10 days)] Missed anticipation: +18.6% from 2026-09-16 to 2026-10-08 (~2.1σ vs typical 10d vol). Target date 2026-09-25 reached; move through 2026-10-08 observed. Confidence 95%.

  • Fri28Aug

    Actual outcome: Mixed · $5.29 at outcome

    The stock closed at $5.29, which is above the bear floor of $4.70 and closer to the bull target of $5.80. The earnings report showed a slight miss on EPS, but the company provided optimistic guidance for the second half of the year, highlighting improved margins and a new strategic partnership. These positive developments, combined with strong forward-looking statements, drove the stock higher despite the earnings miss.

    Zhejiang Hisoar Pharmaceutical is expected to report its H1 2026 results, providing critical insight into whether the Q1 profitability turnaround is sustainable.